Randomized phase II study of sequential carboplatin plus paclitaxel and gefitinib in chemotherapy-naïve patients with advanced or metastatic non-small-cell lung cancer: Long-term follow-up results

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib was initially approved in Japan in 2002 for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC); however, the optimal order of conventional cytotoxic chemotherapy (carboplatin and paclitaxel) and g...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Clin Oncol
Main Authors: Kubo, Emi, Yamamoto, Noboru, Nokihara, Hiroshi, Fujiwara, Yutaka, Horinouchi, Hidehito, Kanda, Shintaro, Goto, Yasushi, Ohe, Yuichiro
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2017
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5244976/
https://ncbi.nlm.nih.gov/pubmed/28123729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2016.1076
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados